Studies on the protective immunity of Schistosoma japonicum bivalent DNA vaccine encoding Sj23 and Sj14
Studies on the protective immunity of Schistosoma japonicum bivalent DNA vaccine encoding Sj23 and Sj14
复制标题
DOI：
10.1016/j.exppara.2006.09.022
复制
发表时间：
2007-04-01
影响因子：
2.1
通讯作者：
Song Deng-xin
中科院分区：
文献类型：
--
作者：
Hu Yuan;Shi You-en;Song Deng-xin
为了探索高效的日本血吸虫双价DNA疫苗，选择脂肪酸结合蛋白（Sj 14）和23 kDa跨膜蛋白（Sj 23）两种蛋白构建DNA疫苗。采用双基因共表达、融合基因表达和两种质粒组合（鸡尾酒疫苗）三种策略成功构建了双价DNA疫苗。通过间接免疫荧光试验（IIF）和逆转录-聚合酶链反应（RT-PCR）证实双价DNA在体外和体内均能良好表达。双价DNA疫苗的免疫保护力明显高于单价DNA疫苗（p < 0.05）。有4组双价疫苗的保护免疫力均高于50%。肉芽肿直径缩小率在18- 39%的范围内。剂量、接种次数、接种途径和末次免疫后攻毒时间4个因素对3个水平的免疫保护效果均无显著影响（P > 0.05）。(c)2006年爱思唯尔公司All rights reserved.
In order to explore the high performance bivalent DNA vaccine of Schistosoma japonicum, the fatty-acid-binding protein (Sj14) and the 23 kDa transmembrane protein (Sj23) two proteins were selected to construct the DNA-based vaccine. It was successful to construct a bivalent DNA vaccine using three strategies: the co-expression of two genes, a fusion gene expression and two kinds of plasmids in combination (cocktail vaccine). The bivalent DNA was proven to express well in vitro and in vivo by indirect immunofluorescence test (IIF) and reverse transcriptase-polymerase chain reaction (RT-PCR). The protective immunity of bivalent DNA vaccine was higher than that of univalent DNA vaccine (p < 0.05). There were four groups of bivalent vaccine whose protective immunity was higher than 50%. Granuloma diameter reduction rates were in the range of 18-39%. There was no significant impact on immunity protection exerted by the four factors including dosage, inoculated times, inoculated routes and challenge time after the last immunization in three levels (P > 0.05). (c) 2006 Elsevier Inc. All rights reserved.